AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large B-cell lymphoma (R/R DLBCL) not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b) and is indicated after two or more lines of systemic therapy in patients who have previously received or are unable to receive CAR-T cell therapy.1 EPKINLY has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit.
In August, EPKINLY was first listed, with specific reimbursement criteria, in Ontario and Quebec, and is now publicly funded in almost all remaining provinces, including Nova Scotia, British Columbia, Saskatchewan, Manitoba, and Newfoundland & Labrador.
“At AbbVie, we are dedicated to the well-being of patients and committed to providing innovative treatments to support their journey,” said Rami Fayed, AbbVie’s Vice President and General Manager in Canada. “It is humbling to see such widespread support for DLBCL patients to quickly access EPKINLY – demonstrating how urgently needed medicines can be brought to patients in a more timely manner.”
ABBV shares decreased in price 29 cents to $188.57 to begin Monday and the week.
